MorphoSys AG Unsponsored ADR (NYSE:MOR) Expected to Announce Earnings of -$0.28 Per Share

Brokerages expect that MorphoSys AG Unsponsored ADR (NYSE:MOR) will announce ($0.28) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for MorphoSys’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.30). MorphoSys posted earnings per share of $0.28 in the same quarter last year, which would indicate a negative year over year growth rate of 200%. The company is expected to report its next earnings report on Monday, November 4th.

On average, analysts expect that MorphoSys will report full year earnings of ($0.94) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.85). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.94) per share, with EPS estimates ranging from ($1.32) to ($0.69). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for MorphoSys.

Shares of NYSE:MOR traded down $0.85 during trading on Friday, reaching $29.76. The company had a trading volume of 3,060 shares, compared to its average volume of 62,613. The business’s fifty day moving average is $27.51. MorphoSys has a twelve month low of $21.75 and a twelve month high of $31.96.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Featured Story: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on MorphoSys (MOR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with's FREE daily email newsletter.